Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market.
Eris product portfolio is primarily focused on therapeutic areas which require the intervention of super specialist and specialist doctors such as Diabetologists, Endocrinologists Cardiologists, and Gastroenterologists.
Eris products in the chronic category cater primarily to the therapeutic areas including cardiovascular, anti-diabetics and neurology, chronic respiratory and chronic pain (analgesics).
In acute category, the product portfolio includes vitamins, gastroenterology, anti-infectives, gynaecology, cute respiratory, acute pain (analgesics), hepatoprotectives, hormones, hematology, dermatology, anti-obesity products and products for injury healing.
Eris Lifescience own and operate a manufacturing facility in Guwahati, Assam. They also outsource the manufacturing of certain of its products to 20 manufacturers. Eris strong sales team comprised of 1,310 marketing representatives.
Eris Lifescience Strengths:
Focus on branded prescription based pharmaceutical products catering to lifestyle related disorders
Portfolio of high volume and leading brands
Focus on metro cities and class 1 towns in India which have higher incidence of lifestyle disorders and concentration of specialists and super specialists
Multi-faceted product selection and engagement model leading to growth in prescription
Strong sales, marketing and distribution capabilities

Eris Lifesciences Limited IPO Stock Quote & Charts

465.00

-2.47%

Check History

• Open: 478.25
• High - Low: 483.05 - 462.35
• Previous Close: 476.80
• Total Traded Volume: 88303
• Updated On: 24-Dec-2019

• 7D
• 15D
• 1M
• 3M
• 1Y